Nuotai Biotech’s Lianyungang plant has passed a GMP compliance inspection for its small‑volume injection (non‑terminally sterilized cartridge) production line and received a compliance notice from the Jiangsu Provincial Medical Products Administration. The line is designed for 200 mln units/year, supports high‑speed, large‑volume, multi‑product runs including suspension processes, and allows flexible expansion, adding contract‑manufacturing capacity for injectables, cartridges and injection‑pen

Nuotai Biotech’s Lianyungang plant has passed a GMP compliance inspection for its small‑volume injection (non‑terminally sterilized cartridge) production line and received a compliance notice from the Jiangsu Provincial Medical Products Administration. The line is designed for 200 mln units/year, supports high‑speed, large‑volume, multi‑product runs including suspension processes, and allows flexible expansion, adding contract‑manufacturing capacity for injectables, cartridges and injection‑pen platforms.